RPID on Nasdaq
RAPID MICRO BIOSYSTEMS, INC.
American laboratory analytical instruments company based in Lexington1
In its 2026 annual report the company says: “We are an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics and cell and gene therapies, vaccines, and sterile injectables.”5 Its shares trade on Nasdaq under the symbol RPID.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with EyePoint Pharmaceuticals, BioNano Genomics or Precipio, Inc., or pick any stock.
- TickerRPID on Nasdaq1
- IndustryLaboratory Analytical Instruments1
- HeadquartersLexington, Massachusetts1
- Incorporated inDE3
- Business address25 Hartwell Avenue, Lexington, Ma 024213
- Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company3
See how the biggest companies compare on our leaderboards
We are leading a global transformation toward fully automated microbial quality control ("MQC") within pharmaceutical manufacturing. Our products safeguard the most complex and critical bioprocessing workflows in the industry, enabling faster, safer, and higher capacity drug production. Through our unique expertise at the intersection of microbiology, robotic systems, and advanced vision algorithms, we are setting the foundation for end-to-end quality control automation to enable the future of advanced pharmaceutical manufacturing.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-141.1%Operating margin2
-140.3%Net margin2
19.7%Revenue growth, 20252
-141.9%Return on equity2
0.57×Debt to equity2
-$31.9MFree cash flow2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 70% of the revenue RAPID MICRO BIOSYSTEMS, INC. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Product | $18.7M | $23.4M |
| Service | $9.3M | $10.2M |
Regions
United States brought in 40% of the revenue RAPID MICRO BIOSYSTEMS, INC. broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $10.6M | $13.4M |
| Switzerland | $5.7M | $6.0M |
| All Other Countries | $6.6M | $5.8M |
| DEMember | $3.0M | $5.8M |
| Japan | $2.1M | $2.6M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development41¢$13.6M
- Other costs59¢$19.9M
- Income tax0¢$40.0K
Out of $33.6M in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $33.6M | $28.1M |
| Research and development | $13.6M | $14.6M |
| Sales and marketing | $12.1M | $13.3M |
| General and administrative | $22.8M | $21.9M |
| Total costs and operating expenses | $81.0M | $78.0M |
| Loss from operations | -$47.4M | -$49.9M |
| Interest income | $1.5M | $3.2M |
| Interest expense | -$1.1M | -$40.0K |
| Other expense, net | -$110.0K | -$112.0K |
| Total other income, net | $309.0K | $3.1M |
| Loss before income taxes | -$47.1M | -$46.9M |
| Income tax expense | $40.0K | $22.0K |
| Net loss | -$47.1M | -$46.9M |
| Net loss per share basic (in dollars per share) | -$1.05 | -$1.08 |
| Net loss per share diluted (in dollars per share) | -$1.05 | -$1.08 |
| Weighted average common shares outstanding - basic (in shares) | 44.7M shares | 43.6M shares |
| Weighted average common shares outstanding - diluted (in shares) | 44.7M shares | 43.6M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $20.0M | $16.9M | |
| Short-term investments | $18.3M | $33.8M | |
| Accounts receivable | $3.1M | $7.5M | |
| Inventory, net | $17.6M | $20.2M | |
| Prepaid expenses and other current assets | $2.1M | $2.5M | |
| Total current assets | $61.2M | $80.9M | |
| Property and equipment, net | $9.0M | $11.2M | |
| Right-of-use assets | $4.1M | $5.2M | |
| Other long-term assets | $319.0K | $531.0K | |
| Restricted cash | $284.0K | $365.0K | |
| Total assets | $74.9M | $98.2M | |
| Accounts payable | $4.1M | $2.5M | |
| Accrued expenses and other current liabilities | $8.3M | $7.2M | |
| Deferred revenue | $4.7M | $6.6M | |
| Lease liabilities, short-term | $1.3M | $1.2M | |
| Total current liabilities | $18.5M | $17.6M | |
| Notes payable, net | $18.9M | $0 | |
| Warrant liability | $186.0K | $0 | |
| Lease liabilities, long-term | $3.7M | $5.0M | |
| Other long-term liabilities | $397.0K | $298.0K | |
| Total liabilities | $41.6M | $22.8M | |
| Preferred stock | $0 | $0 | |
| Additional paid-in capital | $555.1M | $550.2M | |
| Accumulated deficit | -$522.4M | -$475.3M | |
| Accumulated other comprehensive income | $11.0K | $39.0K | |
| Total stockholders equity | $33.2M | $75.4M | $118.0M |
| Total liabilities and stockholders equity | $74.9M | $98.2M | |
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | |
| Preferred stock, authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $20.0M | $16.9M | |
| Short-term investments | $18.3M | $33.8M | |
| Accounts receivable | $3.1M | $7.5M | |
| Inventory, net | $17.6M | $20.2M | |
| Prepaid expenses and other current assets | $2.1M | $2.5M | |
| Total current assets | $61.2M | $80.9M | |
| Property and equipment, net | $9.0M | $11.2M | |
| Right-of-use assets | $4.1M | $5.2M | |
| Other long-term assets | $319.0K | $531.0K | |
| Restricted cash | $284.0K | $365.0K | |
| Total assets | $74.9M | $98.2M | |
| Accounts payable | $4.1M | $2.5M | |
| Accrued expenses and other current liabilities | $8.3M | $7.2M | |
| Deferred revenue | $4.7M | $6.6M | |
| Lease liabilities, short-term | $1.3M | $1.2M | |
| Total current liabilities | $18.5M | $17.6M | |
| Notes payable, net | $18.9M | $0 | |
| Warrant liability | $186.0K | $0 | |
| Lease liabilities, long-term | $3.7M | $5.0M | |
| Other long-term liabilities | $397.0K | $298.0K | |
| Total liabilities | $41.6M | $22.8M | |
| Preferred stock | $0 | $0 | |
| Additional paid-in capital | $555.1M | $550.2M | |
| Accumulated deficit | -$522.4M | -$475.3M | |
| Accumulated other comprehensive income | $11.0K | $39.0K | |
| Total stockholders equity | $33.2M | $75.4M | $118.0M |
| Total liabilities and stockholders equity | $74.9M | $98.2M | |
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | |
| Preferred stock, authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$47.1M | -$46.9M |
| Depreciation and amortization expense | $3.3M | $3.4M |
| Noncash interest expense | $97.0K | $0 |
| Stock-based compensation expense | $4.0M | $3.9M |
| Provision for excess & obsolete inventory | $1.1M | $95.0K |
| Noncash lease expense | $1.2M | $1.2M |
| Gain on revaluation of warrant liability | -$131.0K | $0 |
| Accretion on investments | $351.0K | -$1.0M |
| Other | $34.0K | $34.0K |
| Accounts receivable | $4.4M | -$2.0M |
| Inventory | $1.5M | -$335.0K |
| Prepaid expenses and other current assets | $320.0K | $403.0K |
| Other long-term assets | $64.0K | -$150.0K |
| Accounts payable | $1.6M | $562.0K |
| Accrued expenses and other current liabilities | $28.0K | -$3.9M |
| Other long-term liabilities | $64.0K | $0 |
| Deferred revenue | -$1.9M | $626.0K |
| Net cash used in operating activities | -$31.1M | -$44.2M |
| Purchases of property and equipment | -$850.0K | -$1.4M |
| Purchases of investments | -$27.1M | -$35.0M |
| Sales of investments | $2.5M | $4.0M |
| Maturity of investments | $39.8M | $69.1M |
| Net cash provided by investing activities | $14.3M | $36.7M |
| Proceeds from issuance of Class A common stock - stock option exercise | $491.0K | $7.0K |
| Proceeds from issuance of Class A common stock - employee stock purchase plan | $162.0K | $231.0K |
| Proceeds from issuance of debt | $20.0M | $0 |
| Payments of debt issuance costs | -$878.0K | $0 |
| Issuance of Class A common stock under the ATM offering | $445.0K | $0 |
| Tax withholding on settlement of restricted stock units | -$419.0K | $0 |
| Payments on finance lease obligations | -$30.0K | -$35.0K |
| Net cash provided by financing activities | $19.8M | $203.0K |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $3.0M | -$7.3M |
| Cash paid for interest | $770.0K | $40.0K |
| Purchases of property and equipment in accounts payable/accrued expenses | $12.0K | $309.0K |
| Recognition of warrant liability in connection with debt issuance | $317.0K | $0 |
| Warrant to purchase Class A common stock | $317.0K | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
RAPID MICRO BIOSYSTEMS, INC. sits at the top of its group. 5 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of RAPID MICRO BIOSYSTEMS, INC.
- ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G on RAPID MICRO BIOSYSTEMS, INC., latest Aug 14, 2026
- Bain Capital Life Sciences Fund, L.P. Filed SCHEDULE 13G/A on RAPID MICRO BIOSYSTEMS, INC., latest Aug 14, 2026 (2 filings since Feb 14, 2022)
- Longitude Capital Partners II, LLC Filed SCHEDULE 13G/A on RAPID MICRO BIOSYSTEMS, INC., latest May 15, 2026 (3 filings since Feb 15, 2022)
- Endeavour Medtech Growth II LP Filed SCHEDULE 13G/A on RAPID MICRO BIOSYSTEMS, INC., latest Feb 13, 2026 (3 filings since Feb 2, 2022)
- Robert G. Spignesi Jr. Filed SCHEDULE 13D on RAPID MICRO BIOSYSTEMS, INC., latest Aug 19, 2025
- T. Rowe Price Investment Management, Inc. Filed SC 13G/A on RAPID MICRO BIOSYSTEMS, INC., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
- D1 Capital Partners L.P. Filed SC 13G/A on RAPID MICRO BIOSYSTEMS, INC., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G/A on RAPID MICRO BIOSYSTEMS, INC., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- Colony Harvest Ltd Filed SC 13G/A on RAPID MICRO BIOSYSTEMS, INC., latest Feb 8, 2023 (2 filings since Feb 11, 2022)
- JPMorgan Chase Filed SC 13G/A on RAPID MICRO BIOSYSTEMS, INC., latest Nov 7, 2022 (2 filings since Jan 26, 2022)
- KENNEDY LEWIS MANAGEMENT LP Filed SC 13D/A on RAPID MICRO BIOSYSTEMS, INC., latest Aug 29, 2022 (4 filings since Mar 16, 2022)
- RAPID MICRO BIOSYSTEMS, INC. Lexington, Massachusetts
- Rapid Micro Biosystems Europe GmbH Subsidiary · Germany
- Rapid Micro Biosystems German Holdings LLC Subsidiary · Delaware, United States
- Rapid Micro Biosystems Services Switzerland GmbH Subsidiary · Switzerland
- Rapid Micro Biosystems Swiss Holdings LLC Subsidiary · Delaware, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What RAPID MICRO BIOSYSTEMS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $28.3M2 Dec 31, 2025 | $27.7M2 Dec 31, 2024 | +2.0% |
| Accumulated depreciation | $19.3M2 Dec 31, 2025 | $16.5M2 Dec 31, 2024 | +16.8% |
| Property and equipment, net | $9.0M2 Dec 31, 2025 | $11.2M2 Dec 31, 2024 | −19.8% |
| Finance-lease assets | $129.0K2 Dec 31, 2025 | $165.0K2 Dec 31, 2024 | −21.8% |
| Operating-lease assets (leased space) | $4.0M2 Dec 31, 2025 | $5.0M2 Dec 31, 2024 | −20.3% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $20.0M2 Dec 31, 2025 | $16.9M2 Dec 31, 2024 | +18.4% |
| Marketable securities, current | $18.3M2 Dec 31, 2025 | $33.8M2 Dec 31, 2024 | −46.0% |
| Marketable securities, non-current | $09 Dec 31, 2024 | $2.9M9 Dec 31, 2023 | −100.0% |
| Debt securities available for sale | $18.3M2 Dec 31, 2025 | $33.8M2 Dec 31, 2024 | −46.0% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $17.6M2 Dec 31, 2025 | $20.2M2 Dec 31, 2024 | −12.9% |
| Raw materials | $11.8M2 Dec 31, 2025 | $10.6M2 Dec 31, 2024 | +12.0% |
| Work in process | $884.0K2 Dec 31, 2025 | $372.0K2 Dec 31, 2024 | +137.6% |
| Finished goods | $4.9M2 Dec 31, 2025 | $9.3M2 Dec 31, 2024 | −47.4% |
Properties, in its own words
Our principal office is located in Lexington, Massachusetts, where we sublease 33,339 square feet of office, back-up manufacturing, sales demonstration lab and research and development innovation space, which expires in June 2029. We also lease 67,663 square feet of office, laboratory, manufacturing and inventory-storage space in Lowell, Massachusetts. We lease this space under a lease agreement, as amended, which expires in July 2029. Further, we maintain inventory storage at a warehouse in Oss, Netherlands as well as various offsite warehouses in the United States and Europe. We believe that our facilities are sufficient to meet our current needs.
Item 2 of the 10-K filed Mar 12, 2026.5
Leadership
Who has led RAPID MICRO BIOSYSTEMS, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerRobert G. Spignesi Jr. Jul 14, 2021 to now14
- PresidentRobert G. Spignesi Jr. Jul 14, 2021 to now14
- Chief financial officerSean M. Wirtjes Jul 14, 2021 to now15
- Chief operating officerJohn J. Addington Wilson Jul 14, 2021 to now16
Board members and other officers (12)
- SVP, GC & SecretaryJonathan Paris Feb 15, 2023 to Feb 15, 202317
- Chief Human Resources OfficerVictoria Vezina Jul 14, 2021 to Mar 12, 202418
- CHIEF COMMERCIAL OFFICERRichard A. Keys Oct 5, 2021 to Feb 15, 202219
- Board memberDafni Bika May 27, 2025 to now20
- Board memberKirk Malloy Jul 18, 2023 to now21
- Board memberAlexander Schmitz Jul 14, 2021 to Jul 15, 202122
- Board memberMelinda Litherland Pei Jul 14, 2021 to now23
- Board memberNatale S. Ricciardi Jul 14, 2021 to now24
- Board memberRichard S. Kollender Jul 14, 2021 to now25
- Board memberRobert G. Spignesi Jr. Jul 14, 2021 to now14
- Board memberInese Lowenstein Dec 21, 2021 to now26
- General counselJonathan Paris Jul 14, 2021 to Mar 13, 202327
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Rapid Micro Biosystems Europe GmbH Germany4
- Rapid Micro Biosystems German Holdings LLC Delaware4
- Rapid Micro Biosystems Services Switzerland GmbH Switzerland4
- Rapid Micro Biosystems Swiss Holdings LLC Delaware4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- RAPID MICRO BIOSYSTEMS INCOct 23, 2006 to Jul 15, 20093
Timeline
- Aug 7, 20268-K Results of operations28
- May 28, 20268-K Shareholder vote29
- May 19, 20268-K Entered a material agreement30
- May 13, 20268-K Results of operations31
- Mar 27, 20268-K Executive or director change32
- Mar 12, 20268-K Results of operations; Regulation FD disclosure33
- Jan 13, 20268-K Results of operations34
- Nov 7, 20258-K Results of operations35
- Aug 12, 20258-K Entered a material agreement; Results of operations; New debt or obligation36
- Jun 17, 20258-K Other events37
- May 23, 20258-K Executive or director change; Shareholder vote38
- May 9, 20258-K Results of operations39
- Jul 14, 2021New chief executive Robert G. Spignesi Jr. becomes CEO14
Calendar
Coming up
- Nov 6, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.26) a share, on Nov 7, 2025.40
When it reported results
- Aug 7, 2026Reported quarterly or annual results28
- May 13, 2026Reported quarterly or annual results31
- Mar 12, 2026Reported quarterly or annual results33
- Jan 13, 2026Reported quarterly or annual results34
- Nov 7, 2025Reported quarterly or annual results35
- Aug 12, 2025Reported quarterly or annual results36
- May 9, 2025Reported quarterly or annual results39
- Feb 28, 2025Reported quarterly or annual results41
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
264 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 44 major events, 123 insider forms, 24 large holders, 52 other. The latest 20:
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 7, 202610-Q EDGAR
- Aug 7, 20268-K EDGAR
- Jul 24, 20264 EDGAR
- Jul 24, 20264 EDGAR
- Jul 8, 2026144 EDGAR
- Jul 1, 2026144 EDGAR
- Jun 22, 2026144 EDGAR
- Jun 10, 2026144 EDGAR
- Jun 2, 20264 EDGAR
- Jun 2, 20264 EDGAR
- Jun 2, 20264 EDGAR
- Jun 2, 20264 EDGAR
- Jun 2, 20264 EDGAR
- May 29, 2026SD EDGAR
- May 28, 20268-K EDGAR
- May 26, 20264 EDGAR
- May 26, 20264 EDGAR
- May 26, 20264 EDGAR
The 264 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
42 open-market trades by officers, directors and large owners since October 2021: 23 buys and 19 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 11, 2026 | Wilson John J. AddingtonCHIEF OPERATING OFFICER | Sale | 9,603 | $4.32 | $41.5K | Form 4 |
| Mar 11, 2026 | WIRTJES SEAN MCHIEF FINANCIAL OFFICER | Sale | 7,480 | $4.32 | $32.3K | Form 4 |
| Mar 10, 2026 | Spignesi Robert G. Jr.PRESIDENT AND CEO | Sale | 17,922 | $4.11 | $73.7K | Form 4 |
| Feb 20, 2026 | Wilson John J. AddingtonCHIEF OPERATING OFFICER | Sale | 5,403 | $3.92 | $21.2K | Form 4 |
| Feb 20, 2026 | WIRTJES SEAN MCHIEF FINANCIAL OFFICER | Sale | 17,254 | $3.92 | $67.6K | Form 4 |
| Feb 19, 2026 | Spignesi Robert G. Jr.PRESIDENT AND CEO | Sale | 38,327 | $3.89 | $149.1K | Form 4 |
| Feb 9, 2026 | Wilson John J. AddingtonCHIEF OPERATING OFFICER | Sale | 4,610 | $3.78 | $17.4K | Form 4 |
| Feb 9, 2026 | Spignesi Robert G. Jr.PRESIDENT AND CEO | Sale | 12,840 | $3.78 | $48.5K | Form 4 |
| Feb 9, 2026 | WIRTJES SEAN MCHIEF FINANCIAL OFFICER | Sale | 6,027 | $3.78 | $22.8K | Form 4 |
| Feb 4, 2026 | Longitude Venture Partners II, L.P.10% owner | Sale | 49,000 | $3.88 | $190.1K | Form 4 |
| Feb 3, 2026 | Longitude Prime Partners, LLC10% owner | Sale | 27,500 | $4.24 | $116.6K | Form 4 |
| Feb 2, 2026 | Longitude Prime Partners, LLC10% owner | Sale | 27,500 | $4.25 | $116.9K | Form 4 |
| Jan 30, 2026 | Longitude Prime Partners, LLC10% owner | Sale | 46,000 | $4.54 | $208.8K | Form 4 |
| Jan 23, 2026 | Longitude Prime Partners, LLC10% owner | Sale | 7,739 | $4.06 | $31.4K | Form 4 |
| Jul 14, 2025 | Spignesi Robert G. Jr.PRESIDENT AND CEO | Sale | 11,881 | $3.32 | $39.4K | Form 4 |
| Jul 11, 2025 | Spignesi Robert G. Jr.PRESIDENT AND CEO | Sale | 11,874 | $3.33 | $39.5K | Form 4 |
| Jul 10, 2025 | Spignesi Robert G. Jr.PRESIDENT AND CEO | Sale | 11,617 | $3.40 | $39.5K | Form 4 |
| Jul 9, 2025 | Spignesi Robert G. Jr.PRESIDENT AND CEO | Sale | 11,247 | $3.51 | $39.5K | Form 4 |
| Jul 8, 2025 | Spignesi Robert G. Jr.PRESIDENT AND CEO | Sale | 10,824 | $3.51 | $38.0K | Form 4 |
| Dec 5, 2024 | PEI MELINDA LITHERLANDDirector | Buy | 9,120 | $1.04 | $9.5K | Form 4 |
All 42 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ARMISTICE CAPITAL, LLCSCHEDULE 13G, 1 filing Aug 14, 202642
- Bain Capital Life Sciences Fund, L.P.SCHEDULE 13G/A, 2 filings Feb 14, 2022 to Aug 14, 202643
- Longitude Capital Partners II, LLCSCHEDULE 13G/A, 3 filings Feb 15, 2022 to May 15, 202644
- Endeavour Medtech Growth II LPSCHEDULE 13G/A, 3 filings Feb 2, 2022 to Feb 13, 202645
- Robert G. Spignesi Jr.SCHEDULE 13D, 1 filing Aug 19, 202546
- T. Rowe Price Investment Management, Inc.SC 13G/A, 2 filings Feb 14, 2023 to Feb 14, 202447
- D1 Capital Partners L.P.SC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202348
- PRICE T ROWE ASSOCIATES INC /MD/SC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202349
- Colony Harvest LtdSC 13G/A, 2 filings Feb 11, 2022 to Feb 8, 202350
- JPMorgan ChaseSC 13G/A, 2 filings Jan 26, 2022 to Nov 7, 202251
- KENNEDY LEWIS MANAGEMENT LPSC 13D/A, 4 filings Mar 16, 2022 to Aug 29, 202252
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Robert SpignesiChief Executive Officer | 57 | $663.6K | $3.2M53 |
| 2025 | Sean WirtjesChief Financial Officer | 56 | $465.7K | $1.6M53 |
| 2025 | John Wilson | 58 | $465.7K | $1.1M53 |
| 2024 | Robert SpignesiChief Executive Officer | 57 | $641.2K | $1.3M53 |
| 2024 | Sean WirtjesChief Financial Officer | 56 | $449.9K | $762.9K53 |
| 2024 | Chief Operating Officer | $449.9K | $725.8K53 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 34. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How RAPID MICRO BIOSYSTEMS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARRAPID MICRO BIOSYSTEMS, INC.1
- CIK0001380106
- Employer ID (EIN)20-81216475
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)3826 Laboratory Analytical Instruments1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address25 Hartwell Avenue, Lexington, MA 024211
- Phone978-349-32001
- Shares outstanding40,963,464 Common Class A shares; 4,499,529 Common Class B shares as of Mar 6, 20265
- Public float$103.6M as of Jun 30, 20255
- AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts PCAOB ID 238; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceOct 23, 20061
- Filings328 in all: 4 (129), 8-K (47), 3 (20), 144 (18), 10-Q (16), SC 13G (9), SC 13G/A (9), D (8)1
All 40 form types
S-8 (6), UPLOAD (6), 10-K (5), CORRESP (5), DEF 14A (5), DEFA14A (5), ARS (4), SCHEDULE 13G/A (3), SD (3), 424B5 (2), 8-A12B (2), DRS/A (2), DRSLTR (2), EFFECT (2), REGDEX (2), SEC STAFF LETTER (2), 10-K/A (1), 4/A (1), 424B3 (1), 424B4 (1), CERT (1), D/A (1), DRS (1), PRE 14A (1), S-1 (1), S-1/A (1), S-1MEF (1), S-3 (1), SC 13D (1), SC 13D/A (1), SCHEDULE 13D (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Mar 12, 2026
Quarterly report (10-Q) Aug 7, 2026
Proxy statement (DEF 14A) Apr 8, 2026
Latest 8-K (8-K) Aug 7, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Class A common stock, $0.01 par valueper share | RPID | Nasdaq |
From the cover page of the 10-K filed Mar 12, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks RAPID MICRO BIOSYSTEMS, INC. names in Item 1A of its 10-K filed Mar 12, 2026: 69 risks under these headings, as written.5
- Risks Related to Our Financial Position and Need for Capital
- We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to achieve and maintain positive cash flow and profitability.
- Our limited operating history makes it difficult to evaluate our future prospects and the risks and challenges we may encounter.
- Our business depends on the commercial success of our Growth Direct platform, which may not be achieved or maintained.
- Our operating results have fluctuated significantly in the past and will fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.
- We have in the past and may in the future fail to meet our publicly announced guidance or other expectations about our business and future operating results, which could adversely affect our business, reputation and financial results and cause our stock price to decline.
- If we cannot maintain the level of sales of our Growth Direct systems or the sales of our consumables and services to existing customers declines, our future operating results would be adversely affected.
- Our existing and any future indebtedness could adversely affect our ability to operate our business.
- We may need or otherwise decide to raise additional capital to fund our existing operations, improve our platform or develop and commercialize new products or expand our operations.
- Risks Related to Our Business and Strategy
- Our business relies heavily on establishing and maintaining our position in the market as a leading provider of automated MQC testing.
- We may not be successful in expanding our business with existing customers and driving adoption of our solutions with new customers.
The other 59 risks
- We may not successfully expand our Growth Direct platform to customers who manufacture cell and gene therapies.
- The size of the markets and forecasts of market growth for automated MQC testing and other of our key performance indicators are based on a number of complex assumptions and estimates, and may be inaccurate.
- New product development involves a lengthy and complex process and we may be unable to develop or commercialize products on a timely basis, or at all.
- Our customers use our Growth Direct platform as part of their quality control workflow, which is subject to regulation by the FDA and other comparable regulatory authorities.
- If we are unable to manage our inventory and support demand for existing and future products on the Growth Direct platform, our business could suffer.
- We have limited experience in marketing and sales, and if we are unable to successfully market our products to new and existing customers, address our customers’ needs or to expand our customer base, our business may be adversely affected.
- We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.
- If we cannot compete successfully, we may be unable to increase or sustain our revenue, or achieve and sustain profitability.
- We must develop new products, adapt to rapid and significant technological change and respond to introductions of new products by competitors to remain competitive.
- Due to the significant resources required to enable access in new markets, we must make strategic and operational decisions to prioritize certain markets, products and services. We may expend our resources to access markets and develop products and services that do not yield meaningful revenue or we may fail to capitalize on markets, products or services that may be more profitable or with a greater potential for success.
- The Growth Direct platform may contain undetected errors or defects or may not otherwise meet the expectations of our customers, which means our business, financial condition, results of operations and prospects could suffer.
- Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.
- If we lose key management, cannot recruit qualified employees, directors, officers or other significant personnel or experience increases in our compensation costs, our business may be materially harmed.
- We depend on our information technology ("IT") systems, and any failure of these systems could harm our business.
- Cybersecurity incidents and data breaches, data loss and other disruptions could compromise our confidential and/or proprietary information and other sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.
- We are currently subject to, and may in the future become subject to additional, U.S., state, federal, and foreign laws and regulations imposing obligations on how we collect, store, safeguard and process personal information. Our actual or perceived failure to comply with such obligations could harm our business. Our efforts to comply with such laws could require significant resources and expenses and also impair our efforts to maintain and expand our customer base, and thereby decrease our revenue.
- Like many companies, we use AI and machine learning technologies, including generative AI, to efficiently grow and manage our business. These technologies have increasingly been the focus of attention for lawmakers and regulators around the globe.
- We may evaluate strategic opportunities for our business, including through acquisitions, joint ventures or investments in other companies or technologies that could negatively affect our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense.
- We may not realize the intended benefits of our strategic partnerships and other collaborations, and such relationships may introduce additional risks to our business.
- Activities associated with repair or replacement of our products, including due to warranties we provide on our Growth Direct systems and consumables, could have a material adverse effect on our business, financial condition and results of operations.
- Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.
- International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.
- High inflation rates, and the potential for a change in macroeconomic conditions, could negatively impact our revenues and profitability if increases in the prices of our Growth Direct systems or a decrease in customer spending results in lower sales. In addition, if our costs increase and we are not able to pass along these price increases to our customers, our net income would be adversely affected, and the adverse impact may be material.
- Global economic and political instability and geopolitical events could adversely affect our business, financial condition or results of operations.
- Our employees, consultants and collaborators may engage in misconduct or other improper activities.
- Risks Related to Manufacturing and Supply
- If our primary manufacturing facility or development facility becomes damaged or inoperable or we are required to vacate one or both facilities, our ability to conduct and pursue our manufacturing and/or development efforts would be jeopardized.
- Our manufacturing operations are dependent upon third-party suppliers, including single-source suppliers, making us vulnerable to supply shortages and price fluctuations, which could harm our business.
- We forecast sales to determine requirements for components and materials used in our products, and if our forecasts are incorrect, we may experience delays in shipments or increased inventory costs.
- Shipping is a critical part of our business and any changes in our shipping arrangements or damages or losses sustained during shipping could adversely affect our business, financial condition, results of operations and prospects.
- We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us.
- Risks Related to Our Intellectual Property
- If we are unable to obtain and maintain sufficient intellectual property protection for our technology, including the Growth Direct platform, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be impaired.
- Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time.
- The United States government may exercise certain rights with regard to certain of our inventions developed using government funding.
- If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business could be harmed.
- We may not be able to protect our intellectual property rights throughout the world.
- We may not be able to protect and enforce our trademarks and trade names, or build name recognition in our markets of interest thereby harming our competitive position.
- We may be subject to claims challenging the inventorship and ownership of our patents and other intellectual property.
- We may be involved in litigation claiming that we have infringed on a third party’s intellectual property, which could be time consuming and costly and may adversely affect our business, financial condition, results of operations and prospects.
- We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful.
- Our use of open-source software could compromise our ability to offer our services and subject us to possible litigation.
- Risks Related to Our Common Stock
- The market price of our Class A common stock has been and may continue to be volatile and fluctuate substantially, which could result in substantial losses for our stockholders.
- If our Class A common stock is delisted from The Nasdaq Stock Market LLC, the liquidity of our Class A common stock would be adversely affected and the market price of our common stock could decrease.
- Sales of a substantial number of shares of our Class A common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could depress the market price of our Class A common stock.
- An active trading market for our Class A common stock may not be sustainable.
- Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control all matters submitted to stockholders for approval.
- The dual class structure of our common stock and the option of the holders of shares of our Class B common stock to convert into shares of our Class A common stock may limit our Class A stockholders’ ability to influence corporate matters.
- We are an “emerging growth company,” and a "smaller reporting company," and the reduced disclosure requirements applicable to us may make our Class A common stock less attractive to investors.
- If we fail to maintain effective internal control over financial reporting and effective disclosure controls and procedures, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which may adversely affect investor confidence in our company.
- Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
- Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
- We have been, and may again in the future be, subject to the actions of activist stockholders or unsolicited acquisition proposals, which could cause us to incur substantial costs, divert management’s and the board’s attention and resources, and have an adverse effect on our business and stock price.
- Our restated certificate of incorporation designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.
- Our ability to use our net operating losses ("NOLs")and research and development tax credits to offset future taxable income or income tax liabilities is subject to certain limitations.
- General risk factors
- Our failure or perceived failure to achieve or maintain corporate sustainability practices that meet evolving stakeholder expectations could adversely affect us.
- Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, would be stockholders’ sole source of gain.
- If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline, even if our business is doing well.
- If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Class A common stock.
- We could be subject to securities class action litigation.
- Conditions in the banking system and financial markets, including the failure of banks and financial institutions, could have an adverse effect on our operations and financial results.
Legal proceedings
From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARJonathan Paris, SVP, GC & Secretary
- 18
- 19
- 20SEC EDGARDafni Bika, Board member
- 21SEC EDGARKirk Malloy, Board member
- 22SEC EDGARAlexander Schmitz, Board member
- 23SEC EDGARMelinda Litherland Pei, Board member
- 24SEC EDGARNatale S. Ricciardi, Board member
- 25SEC EDGARRichard S. Kollender, Board member
- 26SEC EDGARInese Lowenstein, Board member
- 27SEC EDGARJonathan Paris, General counsel
- 28SEC EDGARResults of operations
- 29SEC EDGARShareholder vote
- 30SEC EDGAREntered a material agreement
- 31SEC EDGARResults of operations
- 32SEC EDGARExecutive or director change
- 33
- 34SEC EDGARResults of operations
- 35SEC EDGARResults of operations
- 36
- 37SEC EDGAROther events
- 38
- 39SEC EDGARResults of operations
- 40NasdaqNasdaq calendar
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53